Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials

医学 内科学 肿瘤科 免疫疗法 肺癌 危险系数 阿替唑单抗 随机对照试验 荟萃分析 优势比 置信区间 癌症 彭布罗利珠单抗
作者
Yunchang Meng,Qingfeng Zhang,Ranpu Wu,Huijuan Li,Zhaofeng Wang,Yang Yao,Xinjing Li,Zhangxuan Chen,Yanzhuo Gong,Hongbing Liu
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:16: 17588359241284929-17588359241284929 被引量:7
标识
DOI:10.1177/17588359241284929
摘要

Background: Neoadjuvant (NE), adjuvant (AD), and perioperative (PE) immunotherapies have gained validation in early-stage non-small cell lung cancer (NSCLC) trials. However, a comprehensive assessment of their comparative efficacy and safety is lacking. Objectives: To compare the efficacy and safety of NE, AD, and PE immunotherapies in early-stage NSCLC. Design: A systematic review and network meta-analysis using a Bayesian framework. Data sources and methods: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) of immune checkpoint inhibitors plus chemotherapy (CT) for early-stage NSCLC. Hazard ratios (HRs) and odds ratios (ORs) for binary endpoints with 95% confidence intervals (CIs) were calculated. Results: We included 10 RCTs involving 5569 NSCLC patients, categorized as NE, PE, or AD immunotherapy. Indirect comparisons highlighted differences in efficacy between PE and AD immunotherapy, specifically in event-free survival (EFS)/disease-free survival (DFS) (HR = 0.72, 95% CI: 0.53-0.96). NE/PE immunotherapies improved pathologic complete response (pCR) (OR = 7.56, 95% CI: 5.24-10.92), major pathologic response (MPR) (OR = 5.46, 95% CI: 3.97-7.51), and EFS (HR = 0.58, 95% CI: 0.52-0.65), while AD immunotherapy enhanced DFS (HR = 0.78, 95% CI: 0.69-0.90). Overall survival (OS) benefits were seen only with PE immunotherapy (HR = 0.66, 95% CI: 0.55-0.81). PE treatment improved EFS across various subgroups (PD-L1 < 1%, IIIB, squamous, female, without MPR/pCR, epidermal growth factor receptor (EGFR) mutant-negative), except EGFR mutant-positive NSCLC (HR = 0.54, 95% CI: 0.21-1.43). AD (OR = 1.81, 95% CI: 1.20-2.73) and PE (OR = 1.28, 95% CI: 1.10-1.50) immunotherapies were associated with higher grade ⩾3 adverse events. Conclusion: In the three treatment modalities, PE immunotherapy appears to be more effective than AD immunotherapy, with PE showing significant advantages in certain subgroups that NE does not. NE and PE immunotherapy significantly improved pCR, MPR, and EFS, while AD immunotherapy significantly improved DFS in NSCLC patients compared to the control group. However, only PE immunotherapy significantly improved OS. Differences in efficacy between NE and PE across the entire population of resectable NSCLC remain to be explored in additional studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
坚强孤容发布了新的文献求助10
刚刚
清心完成签到,获得积分20
1秒前
1秒前
完美世界的应助被平常寒烟采纳,获得10
1秒前
2秒前
2秒前
林慧宁发布了新的文献求助10
2秒前
DW的应助被清水巍少采纳,获得10
3秒前
学医自救发布了新的文献求助10
4秒前
5秒前
5秒前
hmm完成签到,获得积分10
5秒前
番茄炒蛋发布了新的文献求助10
6秒前
和子完成签到,获得积分10
7秒前
冷酷完成签到,获得积分10
8秒前
Qiiii完成签到,获得积分10
8秒前
hamster666发布了新的文献求助10
9秒前
随缘完成签到 ,获得积分10
10秒前
Lucas的应助被穗岁采纳,获得10
10秒前
mountainbike完成签到,获得积分10
11秒前
丘比特的应助被冷酷采纳,获得30
11秒前
12秒前
堃堃堃完成签到 ,获得积分10
12秒前
科研通AI6.4的应助被Seven采纳,获得10
15秒前
15秒前
秦123发布了新的文献求助10
16秒前
善良的采蓝完成签到,获得积分10
16秒前
烟花的应助被胡平采纳,获得10
16秒前
TAN索完成签到,获得积分10
17秒前
唐俊杰完成签到 ,获得积分10
17秒前
19秒前
细心沂发布了新的文献求助10
20秒前
魁梧的小懒猪完成签到,获得积分10
21秒前
21秒前
24秒前
25秒前
26秒前
随缘发布了新的文献求助10
27秒前
梦M发布了新的文献求助10
27秒前
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186784
求助须知:如何正确求助?哪些是违规求助? 9575092
关于积分的说明 21839541
捐赠科研通 7784418
什么是DOI,文献DOI怎么找? 3434819
关于科研通互助平台的介绍 2559221
邀请新用户注册赠送积分活动 2481682